$DTIL Balance Sheet | Understand Stock

$DTIL

$6.79 +$0.38 (5.93%) Close

$DTIL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current assets:
Cash and cash equivalents
Accounts receivable
Marketable securities
Prepaid expenses
Convertible note receivable
Assets held for sale
Current assets of discontinued operations
Contract asset
Other current assets
Total current assets

Restricted cash
Property, equipment, and software—net
Intangible assets—net
Right-of-use assets—net
Investment in equity securities
Equity method investment
Note receivable—net
Other assets
Noncurrent assets of discontinued operations
Total assets

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued compensation
Accrued clinical and research and development expenses
Accrued research and development expenses
Deferred revenue
Loan payable-current portion
Lease liabilities
Other current liabilities
Current liabilities of discontinued operations
Total current liabilities

Loan payable
Deferred revenue
Lease liabilities
Long term debt—net
Warrant liability
Contract liabilities
Other noncurrent liabilities
Noncurrent liabilities of discontinued operations
Total liabilities
Stockholders’ equity:
Preferred stock: $0.0001 par value— 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock: $0.000005 par value— 200,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 25,832,913 shares issued and 25,805,898 shares outstanding as of June 30, 2026; 24,115,346 shares issued and 24,088,425 shares outstanding as of December 31, 2025
Additional paid-in capital
Accumulated deficit
Treasury stock
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments